Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02580708
• Other study ID #: CO-1686-033
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 30, 2015
• Est. completion date: June 27, 2016

Study information

• Verified date: September 2018
• Source: Clovis Oncology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Description:

This is a Phase 1/2, open-label, non randomized, multicenter study evaluating the safety and efficacy of rociletinib administered in combination with trametinib.

This study will be conducted in 2 phases:

Phase 1: This will be the dose escalation phase of the study. Phase 1 will determine the MAD or MTD and RP2D of the combination of rociletinib and trametinib, and evaluate its safety and tolerability and PK profile in EGFRm NSCLC patients who have failed at least one prior EGFR TKI.

Phase 2: This will be the dose expansion phase. Phase 2 will evaluate the preliminary efficacy and pharmacodynamics of the combination of rociletinib and trametinib at the RP2D in two subsets of EGFRm NSCLC patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: June 27, 2016
• Est. primary completion date: May 5, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study-specific evaluation

• Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion); measurable disease per RECIST 1.1

• Prior treatment with an EGFR TKI; in Phase 2, prior treatment with a T790M-directed EGFR TKI for patients in Group B. Previous chemotherapy is allowed; in Phase 2, immediate prior therapy must be EGFR TKI

• Patient willingness to undergo tumor biopsy at baseline and on treatment (optional for Phase 1; mandatory for Phase 2)

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy at least 3 months

• Adequate hematological and biological function; LVEF =50%

Exclusion Criteria:

• Documented evidence in tumor of exon 20 insertion, small cell transformation, or MET amplification

• Leptomeningeal carcinomatosis or other untreated or symptomatic CNS metastases (asymptomatic CNS metastases allowed if clinically stable without requirement for steroids within 2 weeks)

• Known preexisting interstitial lung disease or pneumonitis

• Concurrent use of QT-prolonging medication

• Uncontrolled diabetes (HA1C > 10%) despite optional therapy

• Cardiac abnormalities:

• Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia's method (QTcF) >450 ms

• Inability to measure QT interval on ECG

• Personal or family history of long QT syndrome

• Implantable pacemaker or implantable cardioverter defibrillator

• Resting bradycardia < 55 beats/min

• Inability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatment

• Presence of serious or unstable concomitant systemic disorder incompatible with the clinical study (eg, substance abuse; uncontrolled intercurrent illness including active infection; arterial thrombosis; unstable respiratory, hepatic, renal or cardiac disease; and other active malignancy)

• Pregnant or breastfeeding females and male or female patients who refuse to use adequate contraception during the study and for 16 weeks after the last dose of study treatment

• Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Rociletinib

• Trametinib

Locations

Country	Name	City	State
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	Virginia Cancer Specialists	Fairfax	Virginia
United States	Tennessee Oncology, PLLC - The Sarah Cannon Research Institute	Nashville	Tennessee
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Clovis Oncology, Inc.	Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events	Treatment emergent adverse events (AEs), laboratory abnormalities and ECG abnormalities in EGFR-mutant NSCLC patients given oral rociletinib in combination with oral trametinib; defining in Phase 1 the recommended combination dose for further evaluation in Phase 2	Continuously, up to approximately 24 months
Primary	Objective Response Rate (ORR)	ORR according to RECIST Version 1.1 as determined by Investigator assessment	Every 6 weeks until disease progression, up to approximately 24 months
Primary	Cmax of rociletinib and trametinib at steady state		Cycle 2 Day 1 to Day 2
Primary	Tmax of rociletinib and trametinib at steady state		Cycle 2 Day 1 to Day 2
Primary	AUC of rociletinib and trametinib at steady state		Cycle 2 Day 1 to Day 2
Primary	Cmin of rociletinib and trametinib at steady state		Cycle 2 Day 1 to Day 2
Primary	t1/2 of rociletinib at steady state		Cycle 2 Day 1 to Day 2
Secondary	Duration of Response (DR) According to RECIST Version 1.1	DR according to RECIST Version 1.1 as determined by Investigator assessment	Every 6 weeks until disease progression, up to approximately 24 months
Secondary	Disease Control Rate (DCR) According to RECIST Version 1.1	DCR according to RECIST Version 1.1 as determined by Investigator assessment	Every 6 weeks until disease progression, up to approximately 24 months
Secondary	Progression Free Survival (PFS) According to RECIST Version 1.1	PFS according to RECIST Version 1.1 as determined by Investigator assessment	Every 6 weeks until disease progression, up to approximately 24 months
Secondary	Overall Survival (OS)		Every 12 weeks until date of death, up to approximately 60 months
Secondary	Longitudinal changes in blood based biomarkers (i.e. mutations in EGFR) in ctDNA		Biomarker samples will be collected from each subject approximately every 3 weeks, up to approximately 24 months
Secondary	Cmax of rociletinib metabolites at steady state		Cycle 2 Day 1 to Day 2
Secondary	Tmax of rociletinib metabolites at steady state		Cycle 2 Day 1 to Day 2
Secondary	AUC of rociletinib metabolites at steady state		Cycle 2 Day 1 to Day 2
Secondary	Cmin of rociletinib metabolites at steady state		Cycle 2 Day 1 to Day 2